185 related articles for article (PubMed ID: 6824571)
21. Serum oestradiol-17 beta, testosterone, luteinizing hormone and follicle-stimulating hormone in males with breast cancer.
Ribeiro GG; Phillips HV; Skinner LG
Br J Cancer; 1980 Mar; 41(3):474-7. PubMed ID: 6770883
[No Abstract] [Full Text] [Related]
22. Serum hormone levels in breast cancer patients and controls in Egypt and Great Britain. The Anglo-Egyptian Health Agreement Collaborative Study.
Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1329-35. PubMed ID: 3181253
[TBL] [Abstract][Full Text] [Related]
23. The effects of chlorotrianisene (Tace) of kinetics of 3H-testosterone metabolism in patients with carcinoma of the prostate.
Baba S; Janetschek G; Pollow K; Hahn K; Jacobi GH
Br J Urol; 1982 Aug; 54(4):393-8. PubMed ID: 6810984
[TBL] [Abstract][Full Text] [Related]
24. Circulating hormone levels in breast cancer patients. correlation with serum tumor markers and the clinical and biological features of the tumors.
Hernández L; Nuñez-Villarl MJ; Martínez-Arribas F; Pollán M; Schneider J
Anticancer Res; 2005; 25(1B):451-4. PubMed ID: 15816610
[TBL] [Abstract][Full Text] [Related]
25. Amenorrhoea in women with non-alcoholic chronic liver disease.
Cundy TF; Butler J; Pope RM; Saggar-Malik AK; Wheeler MJ; Williams R
Gut; 1991 Feb; 32(2):202-6. PubMed ID: 1864542
[TBL] [Abstract][Full Text] [Related]
26. Endogenous sex hormones, prolactin and mammographic density in postmenopausal Norwegian women.
Bremnes Y; Ursin G; Bjurstam N; Rinaldi S; Kaaks R; Gram IT
Int J Cancer; 2007 Dec; 121(11):2506-11. PubMed ID: 17657735
[TBL] [Abstract][Full Text] [Related]
27. Increased plasma prolactin levels in a group of men with breast cancer--a preliminary study.
Olsson H; Alm P; Aspegren K; Gullberg B; Jönsson PE; Ranstam J
Anticancer Res; 1990; 10(1):59-62. PubMed ID: 2110433
[TBL] [Abstract][Full Text] [Related]
28. Plasma prolactin levels in patients with breast cancer.
Rose DP; Pruitt BT
Cancer; 1981 Dec; 48(12):2687-91. PubMed ID: 7306924
[TBL] [Abstract][Full Text] [Related]
29. Effect of a new LH-RH analogue (D-Ser(TBU)6-EA10-LH-RH) on gonadotrophin and gonadal steroid secretion in men.
Wiegelmann W; Solbach HG; Kley HK; Nieschlag E; Rudorff KH; Krüskemper HL
Horm Res; 1976; 7(1):1-10. PubMed ID: 793974
[TBL] [Abstract][Full Text] [Related]
30. Plasma hormones in pre- and postmenopausal breast cancer.
Drafta D; Schindler AE; Milcu SM; Keller E; Stroe E; Horodniceanu E; Bălănescu I
J Steroid Biochem; 1980 Jul; 13(7):793-802. PubMed ID: 6774172
[No Abstract] [Full Text] [Related]
31. Plasma hormone levels in patients with prostatic carcinoma treated with diethylstilboestrol and estramustine.
Bishop MC; Selby C; Taylor M
Br J Urol; 1985 Oct; 57(5):542-7. PubMed ID: 3904908
[TBL] [Abstract][Full Text] [Related]
32. Plasma endothelin and LH-RH, LH, FSH, prolactin, progesterone, 17alpha-hydroxyprogesterone, estrone, 17beta-estradiol, delta4-androstenedione, testosterone, active renin, angiotensin-II and ANP levels in blood and LH, estrone and 17beta-estradiol and pregnanediol levels in urine of normal cycling women.
Usuki S; Kondoh K; Kubo T
J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S421-7. PubMed ID: 11078439
[TBL] [Abstract][Full Text] [Related]
33. Prolactin levels and hormonal profile in postmenopausal patients with advanced breast cancer during endocrine treatments.
Pannuti F; Martoni A; Farabegoli G; Piana E
Chemioterapia; 1985 Apr; 4(2):127-34. PubMed ID: 3159487
[TBL] [Abstract][Full Text] [Related]
34. Diurnal variations and temporal coupling of bioactive and immunoactive luteinizing hormone, prolactin, testosterone and 17-beta-estradiol in adult men.
Juneja HS; Karanth S; Dutt A; Parte P; Meherjee P
Horm Res; 1991; 35(3-4):89-94. PubMed ID: 1806473
[TBL] [Abstract][Full Text] [Related]
35. The influence of chronic exposure to low frequency pulsating magnetic fields on concentrations of FSH, LH, prolactin, testosterone and estradiol in men with back pain.
Woldanska-Okonska M; Karasek M; Czernicki J
Neuro Endocrinol Lett; 2004 Jun; 25(3):201-6. PubMed ID: 15349086
[TBL] [Abstract][Full Text] [Related]
36. [Mastopathy and breast cancer: is there a typical hormone profile?].
Völker W; Leipert KP; Gehrlings H; Stauch G; von zur Mühlen A; Schneider J
Geburtshilfe Frauenheilkd; 1986 May; 46(5):284-9. PubMed ID: 3087811
[TBL] [Abstract][Full Text] [Related]
37. Endogenous hormones and risk of breast cancer in postmenopausal women.
Hankinson SE
Breast Dis; 2005-2006; 24():3-15. PubMed ID: 16917136
[TBL] [Abstract][Full Text] [Related]
38. Relation between plasma hormone profiles, symptoms, and response to oestrogen treatment in women approaching the menopause.
Chakravarti S; Collins WP; Thom MH; Studd JW
Br Med J; 1979 Apr; 1(6169):983-5. PubMed ID: 219937
[TBL] [Abstract][Full Text] [Related]
39. A dose-comparative endocrine-clinical study of leuprorelin in premenopausal breast cancer patients.
Dowsett M; Mehta A; Mansi J; Smith IE
Br J Cancer; 1990 Nov; 62(5):834-7. PubMed ID: 2123115
[TBL] [Abstract][Full Text] [Related]
40. Hormones and the pathophysiology of fibrocystic mastopathy: elevated luteinizing hormone levels.
Golinger RC; Krebs J; Fisher ER; Danowski TS
Surgery; 1978 Aug; 84(2):212-5. PubMed ID: 684613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
